I would not offer endocrine therapy to a woman with PASH. PASH is a benign breast disease and is felt to be mediated by hormonal induced stromal change, hence the ER positivity. Endocrine therapy is offered to women with high risk breast lesions (LCIS, ADH, ALH, etc) primarily to reduce the risk of ...

PASH is a rarely encountered breast lesion and hence large randomized studies have not been conducted exclusively for this disease. Nevertheless, based on small series and retrospective reviews, this disease seems to have an excellent prognosis and in fact, some series have reported a lower risk of ...